ESCRS - FP16.04 - Multicenter Canaloplasty Data Registry – Outcomes Of Ab-Interno Canaloplasty Across Different Glaucoma Types And Severity

Multicenter Canaloplasty Data Registry – Outcomes Of Ab-Interno Canaloplasty Across Different Glaucoma Types And Severity

Published 2023 - 41st Congress of the ESCRS

Reference: FP16.04 | Type: Free paper | DOI: 10.82333/bbf1-k730

Authors: Shamil Patel 1 , Nathan Kerr 2 , David Lubeck 3 , Keith Barton* 4 , Iqbal Ike Ahmed 5

1Eye Physicians and Surgeons of Arizona,Scottsdale,United States, 2Centre for Eye Research Australia,Melbourne,Australia, 3Arbor Centers for EyeCare,Homewood, Illinois,United States, 4Moorfields Eye Hospital,London,United Kingdom, 5University of Utah School of Medicine,Salt Lake City, Utah,United States

Purpose

Collating results from the iTrack Global Data Registry (iTGDR), this study aims to investigate efficacy and safety of ab-interno canaloplasty in reducing IOP and number of medications across all grades of glaucoma severity and types of glaucoma.

Setting

 Cloud-based International Glaucoma Surgery Registry (IGSR).

Methods

Prospective multicenter cloud-based database (iTGDR, part of the International Glaucoma Surgery Registry - IGSR), real-world study including glaucoma patients undergoing canaloplasty with the iTrack or iTrack Advance canaloplasty device (Nova Eye Inc., Fremont, USA). Mean reduction in IOP and number of medications (meds) were the primary endpoints and eyes were grouped based on baseline glaucoma severity (early, moderate, severe, advanced) and glaucoma type.

Results

313 eyes have been enrolled up to March 2023. IOP for primary OAG at baseline and 6 months post-op were 17.5±5.5 and 13.1±3.4 (25% reduction), and meds were 2.2±1.2 and 1.5±1.3 (n=220) respectively. IOP for secondary OAG was 19.6±5.9 and 13 and meds (34% reduction) were 1.8±0.9 and 0.3±0.6 (n=19). IOP for ocular hypertension was 21.9±8.4 and 16.6±2.6 (24% reduction) and meds were 1.3±1.1 and 1±1.4 (n=27). IOP for primary angle closure glaucoma (PACG) was 21.3±6.4 and 13.1±3.7 (38.5% reduction) and meds were 1.9±1.5 and 1±1.2 (n=41). Based on stage: IOP for early, moderate, severe and advanced groups at baseline was 17.8±4.8 (n=138), 17.4±5.8 (n=45), 15.1±4 (n=19) and 17.1±6.8  (n=16) and at 6 months 13.9±3.9, 13.1±3.1, 11.5±2.3 and 11.1±2.5

Conclusions

Ab-interno canaloplasty could effectively reduce IOP and medications use across all types and stages of glaucoma.